Results 111 to 120 of about 7,761,768 (249)

"In vitro" and "in vivo" drug targeting using biotinylated immunoliposomes [PDF]

, 2005
The aim of my thesis was the optimization, characterization and application of a new, innovative drug carrier system which can be used to target pharmaceuticals to diseased tissues and organs.
Schnyder, Anita
core   +1 more source

Unlocking the potential of cell‐permeable nanobodies for intracellular applications

FEBS Letters, EarlyView.
This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés, Luise Franz, Christian P.R. Hackenberger   +2 more
wiley   +1 more source

Graph attention networks for predicting drug-gene association of glucocorticoid in oral squamous cell carcinoma: A comparison with GraphSAGE.

PLoS ONE
BackgroundThe present study evaluates the effectiveness of Graph Attention Networks (GAT) and GraphSAGE in predicting drug-gene interactions for glucocorticoids in oral squamous cell carcinoma, thereby aiding in developing better treatment strategies ...
Monal Yuwanati, Santhanamari Thiyagarajan, Kranti Kiran Reddy Ealla, Yash Jain, Pradeep Kumar Yadalam, Senthil Murugan Mullainathan, Anima Nanda, Samir Sahoo, Daniel Ejim Uti   +8 more
doaj   +1 more source

How structural disorder and polyelectrolyte properties of prothymosin α enable its large interactome

FEBS Letters, EarlyView.
In this review, complexes of the fully disordered and highly negatively charged prothymosin α are collected, described, and discussed. Linked to its poly‐electrostatic character, prothymosin α engages a large interactome through multiple different binding modes ranging from fully disordered complexes to short linear motif (SLiM)‐driven interactions ...
Ketty C. Tamburrini, Freia S. Buus, Benjamin Schuler, Birthe B. Kragelund   +3 more
wiley   +1 more source

Complete list of 1009 drug–gene interactions identified through DrugBank analysis.

Complete list of 1009 drug–gene interactions identified through DrugBank analysis.
Aleksandra Panina (24375685), Robert Fredriksson (27811), Helgi B. Schiöth (7413461), Ayse Arzu Şakul (24375688), Ebrar Altınalan (24375682)   +4 more
core   +1 more source

Drug-Gene Interactions between Genetic Polymorphisms and Antihypertensive Therapy [PDF]

, 2004
Genetic factors may influence the response to antihypertensive medication. A number of studies have investigated genetic polymorphisms as determinants of cardiovascular response to antihypertensive drug therapy.
Psaty, Bruce M, Van Duijn, Cornelia M, Klungel, Olaf H, Dep Farmaceutische wetenschappen, Sub Pharmacotherapy, Theoretical, Verschuren, Monique W M, De Boer, Anthonius, Stricker, Bruno H Ch, Schelleman, Hedi, Kroon, Abraham A, Schelleman, H (Hedi), Stricker, Bruno, Klungel, OH, Kroon, André, Psaty, BM, Boer, A, Duijn, Cornelia, Verschuren, WMM   +17 more
core   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Genetic insights into the shared molecular mechanisms of Crohn’s disease and breast cancer: a Mendelian randomization and deep learning approach

Discover Oncology
The objective of this study was to explore the potential genetic link between Crohn’s disease and breast cancer, with a focus on identifying druggable genes that may have therapeutic relevance.
Zhuang Zhuang Wang, Ju Lin Yang, Zong Yao Zhang, Pei Bin Wang   +3 more
doaj   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source